Inovio Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing the pricing and terms of a public offering of common stock and pre-funded warrants expected to generate approximately $80.5 million in net proceeds.

Key Highlights

  • Offering size: 58,747,235 shares of common stock priced at $1.05 per share, plus pre-funded warrants to purchase up to 12,681,337 shares at $1.049 per warrant.
  • Overallotment exercised in full: Underwriters exercised their 30-day option on November 6, 2026, purchasing 10,714,285 additional shares.
  • Expected net proceeds: Approximately $80.5 million after underwriting discounts, commissions, and estimated offering expenses.
  • Expected closing: On or about November 9, 2026, subject to customary closing conditions.
  • Runway disclosed: The company stated it believes the proceeds, combined with existing cash and short-term investments, will fund operating expenses and capital expenditures into late fourth quarter 2027.
  • Underwriters: Jefferies LLC and Piper Sandler & Co. acted as representatives of the underwriting group.

Inovio's November 2026 Equity Offering: Structure and Terms

According to the filing, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) entered into an underwriting agreement on November 5, 2026, with Jefferies LLC and Piper Sandler & Co. as representatives of several underwriters. The offering covered 58,747,235 shares of common stock at $1.05 per share, alongside pre-funded warrants exercisable for up to 12,681,337 shares at an initial exercise price of $0.001 per share. All shares and pre-funded warrants are being sold by the company, the filing disclosed.

The company granted underwriters a 30-day option to purchase up to 10,714,285 additional shares. The filing reported that this option was exercised in full on November 6, 2026. Net proceeds from the full offering, including the overallotment exercise, are expected to be approximately $80.5 million after deducting underwriting discounts, commissions, and estimated offering expenses payable by the company. The offering was made under a Form S-3 registration statement (File No. 333-297233), declared effective by the SEC on July 10, 2026, and supplemented by a prospectus supplement filed November 5, 2026.

Regarding the pre-funded warrants, the filing noted that a holder, together with affiliates and other attribution parties, may not exercise any portion of a pre-funded warrant if doing so would result in ownership exceeding 9.99% of outstanding common stock immediately after exercise. That threshold may be adjusted by the holder to a lower or higher percentage, not to exceed 19.99% under certain Nasdaq conditions, upon 61 days' notice. Under Item 7.01, the company disclosed that it "believes that the net proceeds from the Offering and its current cash, cash equivalents and short-term investments will be sufficient to fund the Company's operating expenses and capital expenditure requirements into late fourth quarter 2027." The filing identified this statement as forward-looking and subject to risks described in the company's regulatory filings.

What Was Disclosed

Inovio disclosed the pricing, structure, and expected net proceeds of a public equity offering, the full exercise of an underwriter overallotment option, and a cash runway estimate extending into late fourth quarter 2027, all via a Form 8-K filed November 9, 2026.